Raj. CHO - 2023: India's first indigenously developed vaccine for the prevention of Cervical cancer is -

Raj. CHO - 2023

Pharmacology

Easy

Appeared in: Raj. CHO - 2023

Explanation

CERVAVAC is India's first indigenously developed Quadrivalent Human Papillomavirus (qHPV) vaccine.
It was developed by the Serum Institute of India (SII) in collaboration with the Department of Biotechnology (DBT).
The vaccine targets four common HPV types: 6, 11, 16, and 18.
This development is a significant milestone for India's public health, aiming to make cervical cancer prevention more affordable and accessible.

Option A: The MMR vaccine provides immunity against Measles, Mumps, and Rubella, which are unrelated to the Human Papillomavirus (HPV) that causes cervical cancer.
Option C: Although GARDASIL is a widely used HPV vaccine that prevents cervical cancer, it is not indigenous to India. It was developed by the American pharmaceutical company Merck.
Option D: CERVARIX is an HPV vaccine, but it is not indigenous to India. It was developed by the British/Belgian company GlaxoSmithKline (GSK). Additionally, it is a bivalent vaccine, targeting only two HPV strains.

Visual 1: Infographic: A comparative chart of HPV vaccines (CERVAVAC, GARDASIL, CERVARIX) detailing their type (bivalent, quadrivalent), target HPV strains, developer, and country of origin.
Visual 2: Diagram: Illustration of the cervix showing how HPV infection can progress to cervical cancer, highlighting the importance of vaccination.

Clinical Relevance

Nursing practice connection: This is primarily an exam-oriented knowledge point with limited direct bedside application, so retain Indigenous vaccine development for cervical cancer prevention in India as background academic context rather than a clinical decision trigger.
The availability of an indigenous HPV vaccine like CERVAVAC is a major step towards reducing the high incidence of cervical cancer in India, which accounts for a significant portion of the global burden.
Nurses play a critical role in educating the public, especially parents of adolescent girls, about the safety, efficacy, and importance of HPV vaccination as part of routine immunization.
What if the question asked for the first HPV vaccine to be licensed globally? In that case, Gardasil (approved in 2006) would be the correct answer, as it preceded other vaccines in widespread use.

How to Approach the Question

First, carefully read the question and identify the most important keywords: 'India's first', 'indigenously developed', and 'Cervical cancer'.
The phrase 'indigenously developed' is the key differentiator. It means the vaccine must have been researched and manufactured within India.
Evaluate each option against this primary criterion.
Eliminate MMR immediately, as it is a vaccine for different diseases (Measles, Mumps, Rubella).
Consider the remaining options: CERVAVAC, GARDASIL, and CERVARIX. Recall or deduce that Gardasil and Cervarix are well-established international brands.
By elimination, CERVAVAC remains as the most likely candidate for an Indian-developed vaccine, which is factually correct.

Concept Tested & Keywords

Concept Tested: Indigenous vaccine development for cervical cancer prevention in India.
Stem keywords: India's first, indigenously developed, vaccine, Cervical cancer
Lead-in keywords: is